These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
89 related articles for article (PubMed ID: 9498716)
1. Plasma soluble interleukin-2 receptors in patients with myelodysplastic syndromes. Yokose N; Ogata K Leuk Lymphoma; 1997 Dec; 28(1-2):171-6. PubMed ID: 9498716 [TBL] [Abstract][Full Text] [Related]
2. Plasma soluble interleukin-2 receptor level in patients with primary myelodysplastic syndromes: a relationship with disease subtype and clinical outcome. Ogata K; Yokose N; An E; Kamikubo K; Tamura H; Dan K; Sakamaki H; Onozawa Y; Hamaguchi H; Nomura T Br J Haematol; 1996 Apr; 93(1):45-52. PubMed ID: 8611474 [TBL] [Abstract][Full Text] [Related]
3. Elevated plasma soluble interleukin 2 receptor level correlates with defective natural killer and CD8+ T-cells in myelodysplastic syndromes. Yokose N; Ogata K; Ito T; An E; Tamura H; Dan K; Hamaguchi H; Sakamaki H; Onozawa Y; Nomura T Leuk Res; 1994 Oct; 18(10):777-82. PubMed ID: 7934136 [TBL] [Abstract][Full Text] [Related]
4. Interleukin-2 therapy for myelodysplastic syndrome: does it work? Ogata K; Yokose N; Nomura T Leuk Lymphoma; 1995 May; 17(5-6):411-5. PubMed ID: 7549831 [TBL] [Abstract][Full Text] [Related]
5. Plasma soluble interleukin-2 receptor (sIL-2R) levels in patients with acute leukemia. Moon Y; Kim Y; Kim M; Lim J; Kang CS; Kim WI; Shim SI; Chung NG; Park YH; Min WS; Han K Ann Clin Lab Sci; 2004; 34(4):410-5. PubMed ID: 15648782 [TBL] [Abstract][Full Text] [Related]
6. Detection of soluble IL-2 receptor in the serum of patients with myelodysplastic syndromes: induction under therapy with GM-CSF. Zwierzina H; Herold M; Schöllenberger S; Geissler D; Schmalzl F Br J Haematol; 1991 Nov; 79(3):438-43. PubMed ID: 1751371 [TBL] [Abstract][Full Text] [Related]
7. High level of soluble interleukin-2 receptor in serum predicts treatment resistance and poor progression-free survival in multiple myeloma. Wang L; Wang JH; Liu WJ; Wang WD; Wang H; Chen XQ; Geng QR; Lu Y; Xia ZJ Ann Hematol; 2017 Dec; 96(12):2079-2088. PubMed ID: 28871325 [TBL] [Abstract][Full Text] [Related]
13. Clinical relevance of serum soluble interleukin-2 receptor levels in acute and chronic graft-versus-host disease. Kobayashi S; Imamura M; Hashino S; Tanaka J; Asaka M Leuk Lymphoma; 1997 Dec; 28(1-2):159-69. PubMed ID: 9498715 [TBL] [Abstract][Full Text] [Related]
14. Interleukin-2 receptor levels in sera of patients with rheumatoid arthritis treated with sulfasalazine, parenteral gold, or placebo. Merkel PA; Dooley MA; Dawson DV; Pisetsky DS; Polisson RP J Rheumatol; 1996 Nov; 23(11):1856-61. PubMed ID: 8923356 [TBL] [Abstract][Full Text] [Related]
15. Soluble interleukin-2 receptor levels correlated with positive symptoms during quetiapine treatment in schizophrenia-spectrum disorders. Igue R; Potvin S; Bah R; Stip E; Bouchard RH; Lipp O; Gendron A; Kouassi E Prog Neuropsychopharmacol Biol Psychiatry; 2011 Aug; 35(7):1695-8. PubMed ID: 21627977 [TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of plasma IL-2 and sIL-2Rα in patients with first-ever ischaemic stroke. Zhao H; Li F; Huang Y; Zhang S; Li L; Yang Z; Wang R; Tao Z; Han Z; Fan J; Zheng Y; Ma Q; Luo Y J Neuroinflammation; 2020 Aug; 17(1):237. PubMed ID: 32795376 [TBL] [Abstract][Full Text] [Related]
17. Plasma soluble interleukin-2 receptor in patients with primary myelofibrosis. Wang JC; Wang A Br J Haematol; 1994 Feb; 86(2):380-2. PubMed ID: 8199029 [TBL] [Abstract][Full Text] [Related]
18. Clinical utility of soluble interleukin-2 receptor in hemophagocytic syndromes: a systematic scoping review. Lin M; Park S; Hayden A; Giustini D; Trinkaus M; Pudek M; Mattman A; Schneider M; Chen LYC Ann Hematol; 2017 Aug; 96(8):1241-1251. PubMed ID: 28497365 [TBL] [Abstract][Full Text] [Related]
19. Higher fetuin-A, lower adiponectin and free leptin levels mediate effects of excess body weight on insulin resistance and risk for myelodysplastic syndrome. Dalamaga M; Karmaniolas K; Chamberland J; Nikolaidou A; Lekka A; Dionyssiou-Asteriou A; Mantzoros CS Metabolism; 2013 Dec; 62(12):1830-9. PubMed ID: 24140093 [TBL] [Abstract][Full Text] [Related]
20. Serum-soluble interleukin-2 receptor (sIL-2R) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma: in combination with the International Prognostic Index. Goto H; Tsurumi H; Takemura M; Ino-Shimomura Y; Kasahara S; Sawada M; Yamada T; Hara T; Fukuno K; Goto N; Okuno M; Takami T; Seishima M; Moriwaki H J Cancer Res Clin Oncol; 2005 Feb; 131(2):73-9. PubMed ID: 15503137 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]